AR118407A1 - MULTIVALENT VACCINE COMPOSITION - Google Patents

MULTIVALENT VACCINE COMPOSITION

Info

Publication number
AR118407A1
AR118407A1 ARP190100353A ARP190100353A AR118407A1 AR 118407 A1 AR118407 A1 AR 118407A1 AR P190100353 A ARP190100353 A AR P190100353A AR P190100353 A ARP190100353 A AR P190100353A AR 118407 A1 AR118407 A1 AR 118407A1
Authority
AR
Argentina
Prior art keywords
antigen
ipv
aluminum hydroxide
rotavirus
antigens
Prior art date
Application number
ARP190100353A
Other languages
Spanish (es)
Original Assignee
Serum Institute Of India Pvt Ltd
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd, Us Health filed Critical Serum Institute Of India Pvt Ltd
Priority to ARP190100353A priority Critical patent/AR118407A1/en
Publication of AR118407A1 publication Critical patent/AR118407A1/en

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a una vacuna o vacunas de combinación inmunogénica estables que comprenden una mezcla de antígenos para la prevención y profilaxis de infecciones causadas por el rotavirus, el virus de la poliomielitis, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis y el virus de la Hepatitis B. La presente proporciona en particular una vacuna de combinación multivalente que comprende: i) antígenos de IPV Salk o IPV Sabin (IPV) en dosis significativamente reducida, preparados mediante la utilización de métodos mejorados de inactivación de formaldehído y adsorción de hidróxido de aluminio, que dan como resultado la recuperación máxima del antígeno D y ii) antígeno(s) de rotavirus inactivado por calor e inyectable obtenido de cepas de rotavirus (CDC-9) que proporcionan una amplia inmunidad de protección cruzada entre las cepas de rotavirus humano, iii) conjugado de PRP de Hib-proteína transportadora que tiene estabilidad e inmunogenicidad mejoradas en donde dicho conjugado de PRP Hib-proteína transportadora es inicialmente preparado usando un nuevo proceso de conjugación y posteriormente se mezcla a baja temperatura en presencia de un estabilizador para minimizar la liberación de PRP libre, iv) antígeno de pertussis de células completas con inmunogenicidad y estabilidad mejoradas obtenidas mediante la adición de antígeno de pertussis de células enteras en una etapa posterior en una mezcla, minimizando así la degradación basada en hidrólisis, v) fracciones homogéneas de toxoide de difteria y toxoide tetánico obtenidos mediante la eliminación de agregados no deseados por el uso de cromatografía por permeación en gel. También se describe el proceso para producir estas composiciones de vacunas inmunogénicas estables mediante las etapas de i) adsorber individualmente IPV en dosis reducida, antígenos de IPV en el hidróxido de aluminio, manteniendo el otro antígeno(s) no absorbido o adsorbido en fosfato de aluminio, hidróxido de aluminio, en una combinación de hidróxido de aluminio y fosfato de aluminio y ii) utilizar un orden particular de adición de antígenos durante la mezcla.This refers to a stable immunogenic combination vaccine or vaccines comprising a mixture of antigens for the prevention and prophylaxis of infections caused by rotavirus, polio virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and the Hepatitis B virus. The present provides in particular a multivalent combination vaccine comprising: i) IPV Salk or IPV Sabin (IPV) antigens in significantly reduced doses, prepared using improved formaldehyde inactivation and adsorption methods. aluminum hydroxide, resulting in maximum recovery of D antigen and ii) injectable heat-inactivated rotavirus antigen (s) derived from rotavirus strains (CDC-9) that provide broad cross-protective immunity between strains of human rotavirus, iii) Hib PRP-carrier protein conjugate having stability and immunogenicity improved quality wherein said PRP Hib-carrier protein conjugate is initially prepared using a new conjugation process and subsequently mixed at low temperature in the presence of a stabilizer to minimize the release of free PRP, iv) whole cell pertussis antigen with improved immunogenicity and stability obtained by adding whole cell pertussis antigen at a later stage in a mixture, thus minimizing degradation based on hydrolysis, v) homogeneous diphtheria toxoid and tetanus toxoid fractions obtained by removing unwanted aggregates by the use of gel permeation chromatography. Also described is the process to produce these stable immunogenic vaccine compositions by the steps of i) individually adsorbing IPV in reduced dose, IPV antigens on aluminum hydroxide, keeping the other antigen (s) unabsorbed or adsorbed on aluminum phosphate. , aluminum hydroxide, in a combination of aluminum hydroxide and aluminum phosphate and ii) using a particular order of antigen addition during mixing.

ARP190100353A 2019-02-13 2019-02-13 MULTIVALENT VACCINE COMPOSITION AR118407A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP190100353A AR118407A1 (en) 2019-02-13 2019-02-13 MULTIVALENT VACCINE COMPOSITION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP190100353A AR118407A1 (en) 2019-02-13 2019-02-13 MULTIVALENT VACCINE COMPOSITION

Publications (1)

Publication Number Publication Date
AR118407A1 true AR118407A1 (en) 2021-10-06

Family

ID=78803795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100353A AR118407A1 (en) 2019-02-13 2019-02-13 MULTIVALENT VACCINE COMPOSITION

Country Status (1)

Country Link
AR (1) AR118407A1 (en)

Similar Documents

Publication Publication Date Title
PH12019500404A1 (en) Multivalent vaccine composition
CO2020001765A2 (en) An immunogenic composition having improved stability, enhanced immunogenicity, and reduced reactogenicity and process for the preparation thereof
AU2021269395B2 (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
PE20100366A1 (en) NOVEL COMPOSITIONS OF VACCINE WITH CELLULAR WHOOUS COUGH AS WELL AS THE METHOD FOR ITS ELABORATION
SI9720050B (en) Multivalent dtp-polio vaccines
BRPI0810778A2 (en) kit, combined vaccine, and methods of decreasing crm neighborhood interference over a sensitive antigen in a primary immunization schedule of a vaccine, and decreasing neighborhood interference over a sensitive antigen, and use of saccharide conjugates
AR092896A1 (en) IMMUNOGENIC COMPOSITIONS
RU2013136397A (en) COMBINED SEVIVALENT VACCINE
PE20211648A1 (en) COMPOSITION OF COMBINED VACCINE INCLUDING REDUCED DOSES OF INACTIVATED POLIO VIRUS AND METHOD OF PREPARING IT
AR118407A1 (en) MULTIVALENT VACCINE COMPOSITION
RU2015111987A (en) Unstitched acellular pertussis antigens for use in combination vaccines
AR067471A1 (en) A COMPONENT OF ANTI-PERTUSSIS VACCINE AND SIMPLIFIED PROCEDURE TO OBTAIN PERTACTIN (PRN) FROM BORDETELLA PERTUSSIS
US11793869B2 (en) Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
ES2224252T3 (en) VACCINE COMPOSITION THAT INCLUDES FRAGMENTS OF THE BORDETELLA PERTUSSIS EXTERNAL MEMBRANE PROTEIN.
OA20569A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.
EA043682B1 (en) COMBINED VACCINE AND METHOD OF ITS PRODUCTION (OPTIONS)
Al-Jadiry Childhood Immunization
AR097217A1 (en) IMMUNOGEN COMBINATION COMPOSITIONS